Michigan strips two clerks in small town of election duties over hand count plan
What you need to know about the 2024 US presidential election
BOJ to keep rates steady as politics muddles outlook
IMF board approves Kenya's reviews, unlocking access to $606 million
Siemens to buy engineering software firm Altair for $10.6 billion
Accuser of Sean 'Diddy' Combs cannot remain anonymous, judge rules
‘Emily in Paris’ star Lucas Bravo mulling exit from show because he’s ‘frustrated’ with his character’s direction
Second gambler admits trying to cash in on scheme involving ex-NBA player Jontay Porter
(Reuters) - Agilent Technologies said on Monday it will acquire contract drug manufacturer Biovectra for $925 million to expand its portfolio of services offered to biotech companies and medical researchers.
Canada-based Biovectra offers fill-and-finish services for drug manufacturers. It also operates a business that makes active ingredients for complex drugs and has expertise in fast-growing segments such as the GLP-1 weight loss drugs, Agilent said.
Agilent has been struggling with soft demand for medical tools and equipment used in clinical studies as its biotech clients face a funding crunch.
The company said it will fund the transaction using a mix of cash on hand and debt financing, adding that Biovectra will become a part of its diagnostics and genomics unit.
The deal will have a dilutive impact of 5 cents on Agilent's profit, a year after the close of the Biovectra transaction.
Biovectra, previously a unit of Mallinckrodt, was acquired by private equity firm H.I.G. Capital in 2019 for $250 million.
(Reporting by Mariam Sunny in Bengaluru; Editing by Shounak Dasgupta)
